Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

References

• Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schroder H, Oellerich M. (2005). Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 27:315–21.
   PubMed Web of Science ®Google Scholar
• Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. (2007). C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8:1127–41.
   PubMed Web of Science ®Google Scholar
• Basu NK, Kole L, Kubota S, Owens IS. (2004). Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Disposit 32:768–73.
   PubMed Web of Science ®Google Scholar
• Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, Robert J. (2008). Functional study of the 830C > G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 61:481–8.
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Disposit 32:775–8.
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinet 34:429–55.
   PubMed Web of Science ®Google Scholar
• Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. (2004). Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528–35.
   PubMed Web of Science ®Google Scholar
• Heymann E, Krisch K. (1967). Phosphoric acid-bis-(p-nitro- phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe-Seyler’s Zeitschrift fur Physiologische Chemie 348:609–19.
   PubMedGoogle Scholar
• Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T. (1995). Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Disposit 23:1022–7.
   PubMed Web of Science ®Google Scholar
• Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. (2000). Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189–92.
   PubMed Web of Science ®Google Scholar
• Inoue K, Miura M, Satoh S, Kagaya H, Saito M, Habuchi T, Suzuki T. (2007). Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 29:299–304.
   PubMed Web of Science ®Google Scholar
• Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, et al. (2007). Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:279–88.
   PubMed Web of Science ®Google Scholar
• Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. (2006). Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi 126:1357–62.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. (2005). The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351–61.
   PubMed Web of Science ®Google Scholar
• Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. (2004). Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84:661–8.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. (2007). Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161–9.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Suzuki T. (2008). Limited sampling strategy for simultaneous estimation of the area under the concentration–time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 30:52–9.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–84.
   PubMed Web of Science ®Google Scholar
• Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. (2005). Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Disposit 33:139–46.
   PubMed Web of Science ®Google Scholar
• Probst MR, Beer M, Beer D, Jeno P, Meyer UA, Gasser R. (1994). Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. J Biol Chem 269:21650–6.
   PubMed Web of Science ®Google Scholar
• Probst MR, Jeno P, Meyer UA. (1991). Purification and characterization of a human liver arylacetamide deacetylase. Biochem Biophys Res Comm 177:453–9.
   PubMed Web of Science ®Google Scholar
• Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. (1998). Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 65:248–52.
   PubMed Web of Science ®Google Scholar
• Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y, Suzuki T, Habuchi T. (2006). Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82:486–93.
   PubMed Web of Science ®Google Scholar
• Satoh T, Hosokawa M. (1998). The mammalian carboxylesterases: from molecules to functions. Ann Rev Pharmacol Toxicol 38:257–88.
   PubMed Web of Science ®Google Scholar
• Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. (2002). Current progress on esterases: from molecular structure to function. Drug Metab Disposit 30:488–93.
   PubMed Web of Science ®Google Scholar
• Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, et al. (1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–69.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. (2001). Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23.305–15.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. (1997). Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Disposit 25:1157–64.
   PubMed Web of Science ®Google Scholar
• Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. (2007). Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 81:924–32.
   PubMed Web of Science ®Google Scholar
• Wu MH, Yan B, Humerickhouse R, Dolan ME. (2002). Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 8:2696–700.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang W, Ma MK, McLeod HL. (2002). Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605–11.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, et al. (2006). Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147–55.
   PubMed Web of Science ®Google Scholar